Comparison of olanzapine long-acting injection and oral olanzapine: A 2-year, randomized, open-label study in outpatients with schizophrenia

Journal of Clinical Psychopharmacology

Volumn 34, Issue 4, 2014, Pages 426-434

  Detke, Holland C ^a   Weiden, Peter J ^b   Llorca, Pierre Michel ^c   Choukour, Moutaz ^d   Watson, Susan B ^a   Brunner, Elizabeth ^a   Ascher Svanum, Haya ^a  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^d I3 Statprobe   (United States)

Author keywords

effectiveness; long acting injection; olanzapine; pamoate; schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; BENZODIAZEPINE; BIPERIDEN; CHLORPROMAZINE; CHOLESTEROL; CREATININE; GLUCOSE; HALOPERIDOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LORAZEPAM; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLANZAPINE; PHOSPHOTRANSFERASE; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL; ZIPRASIDONE; BENZODIAZEPINE DERIVATIVE; DELAYED RELEASE FORMULATION; NEUROLEPTIC AGENT;

ABSCESS; ADULT; AGED; AKATHISIA; ANXIETY DISORDER; ARTICLE; BRONCHITIS; CHOLESTEROL BLOOD LEVEL; CLINICAL GLOBAL IMPRESSION SCALE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFECT; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DSM-IV; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPERTENSION; INCREASED APPETITE; INFLUENZA; INJECTION SITE ERYTHEMA; INJECTION SITE MASS; INJECTION SITE NODULE; INJECTION SITE PAIN; INJECTION SITE REACTION; INSOMNIA; INTENTION TO TREAT ANALYSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MULTICENTER STUDY; OPEN STUDY; PATIENT COMPLIANCE; PATIENT SATISFACTION; PNEUMONIA; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RHINOPHARYNGITIS; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; SUICIDE ATTEMPT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT CHANGE; ADMINISTRATION AND DOSAGE; AMBULATORY CARE; CLINICAL TRIAL; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; INTRAMUSCULAR DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PROCEDURES; TIME; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; PATIENT SATISFACTION; SCHIZOPHRENIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 84903790263     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000140     Document Type: Article

References (34)

1. Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63:892-909. (Pubitemid 35231730)
2. Valenstein M, Ganoczy D, McCarthy JF, et al. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry. 2006;67:1542-1550. (Pubitemid 44787436)
3. Weiden PJ, Zygmunt A. The road back: working with the severely mentally ill. Medication noncompliance in schizophrenia: I. assessment. J Pract Psychiatry Behav Health. 1997;3:106-110.
4. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56:241-247. (Pubitemid 29125132)
5. Weiden PJ, Kozma C, Grogg A, et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004;55:886-891. (Pubitemid 39025215)
6. Lauriello J, Lambert T, Andersen S, et al. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry. 2008;69:790-799. (Pubitemid 351838688)
7. Kane JM, Detke HC, Naber D, et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry. 2010;167:181-189.
8. Schooler NR. Relapse and rehospitalization: comparing oral and depot antipsychotics. J Clin Psychiatry. 2003;64(suppl 16):14-17. (Pubitemid 37523323)
9. Detke HC, Zhao F, Garhyan P, et al. Dose correspondence between olanzapine long-acting injection and oral olanzapine: recommendations for switching. Int Clin Psychopharmacol. 2011;26:35-42.
10. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med. 2002;346:16-22. (Pubitemid 34438915)
11. Kalali A. Patient satisfaction with, and acceptability of, atypical antipsychotics. Curr Med Res Opin. 1999;15:135-137. (Pubitemid 29306745)
12. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13:177-183. (Pubitemid 13132147)
13. Reinhard SC, Gubman GD, Horwitz AV. Burden assessment scale for families of the seriously mentally ill. Eval Program Plan. 1994;17:261-269. (Pubitemid 124011155)
14. Schooler NR, Keith SJ, Severe JB, et al. Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment. Arch Gen Psychiatry. 1997;54:453-463. (Pubitemid 27198207)
15. Levine SZ, Rabinowitz J, Engel R, et al. Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI. Schizophr Res. 2008;98:318-322. (Pubitemid 350235891)
16. Detke HC, McDonnell DP, Brunner E, et al. Post-injection delirium/ sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases. BMC Psychiatry. 2010;10:43.
17. American Diabetes Association. Standards of medical care in diabetesV2010. Diabetes Care. 2010;33:S11-S61.
18. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
19. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676. (Pubitemid 19154942)
20. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
21. National Institute of Mental Health. Abnormal Involuntary Movement Scale (AIMS). In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology, Revised. Rockville, MD: US National Institutes of Health; 1976:534-537.
22. Kantrowitz JT, Citrome L. Olanzapine: review of safety 2008. Expert Opin Drug Saf. 2008;7:761-769.
23. Haddad PM, Taylor M, Niaz OS. First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies. Br J Psychiatry Suppl. 2009;52:S20-S28.
24. Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol. 2005;15:111-117. (Pubitemid 39574406)
25. Rosenheck RA, Krystal JH, Lew R, et al. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med. 2011;364:842-851.
26. Kirson NY, Weiden PJ, Yermakov S, et al. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry. 2013;74:568-575.
27. Agid O, Foussias G, Remington G. Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention. Expert Opin Pharmacother. 2010;11:2301-2317.
28. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Available at: http://psychiatryonline.org/ content.aspx?bookid = 28§ionid = 1665359. Accessed January 15, 2014.
29. National Institute for Health and Clinical Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care (clinical guideline 82). Available at: http://guidance.nice.org.uk/CG82. Accessed January 15, 2014.
30. Shi L, Asher-Svanum H, Zhu B, et al. Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatr Serv. 2007;58:482-488. (Pubitemid 46640638)
31. West JC, Marcus SC, Wilk J, et al. Use of depot antipsychotic medications for medication nonadherence in schizophrenia. Schizophr Bull. 2008;34:995-1001.
32. Ascher-Svanum H, Peng X, Faries D, et al. Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients. BMC Psychiatry. 2009;9:46.
33. Bowen J, Hirsch S. Recruitment rates and factors affecting recruitment for a clinical trial of a putative anti-psychotic agent in the treatment of acute schizophrenia. Hum Psychopharmacol Clin Exp. 1992;7:337-341. (Pubitemid 23076878)
34. Hofer A, Hummer M, Huber R, et al. Selection bias in clinical trials with antipsychotics. J Clin Psychopharmacol. 2000;20:699-702.